These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

306 related items for PubMed ID: 21324723

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. [Microbiological characteristics of pathogens causing bacteremia among hospitalized pediatric oncology patients with fever and neutropenia].
    Leibson T, Ben-Shimol S, Hazan G, Fruchtman Y, Kapelushnik J, Greenberg D.
    Harefuah; 2012 Oct; 151(10):592-6, 603-4. PubMed ID: 23316669
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. The epidemiology of bacteremia with febrile neutropenia: experience from a single center, 1988-2004.
    Paul M, Gafter-Gvili A, Leibovici L, Bishara J, Levy I, Yaniv I, Shalit I, Samra Z, Pitlik S, Konigsberger H, Weinberger M.
    Isr Med Assoc J; 2007 Jun; 9(6):424-9. PubMed ID: 17642387
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. High-risk febrile neutropenia in Auckland 2003-2004: the influence of the microbiology laboratory on patient treatment and the use of pathogen-specific therapy.
    Ritchie S, Palmer S, Ellis-Pegler R.
    Intern Med J; 2007 Jan; 37(1):26-31. PubMed ID: 17199841
    [Abstract] [Full Text] [Related]

  • 28. Counterpoint: routine anti-bacterial prophylaxis is not indicated in neutropenic patients with hematological malignancies.
    Kleinberg M.
    J Natl Compr Canc Netw; 2004 Sep; 2(5):445-51. PubMed ID: 19780253
    [Abstract] [Full Text] [Related]

  • 29. Incidence and clinical impact of extended-spectrum-beta-lactamase (ESBL) production and fluoroquinolone resistance in bloodstream infections caused by Escherichia coli in patients with hematological malignancies.
    Trecarichi EM, Tumbarello M, Spanu T, Caira M, Fianchi L, Chiusolo P, Fadda G, Leone G, Cauda R, Pagano L.
    J Infect; 2009 Apr; 58(4):299-307. PubMed ID: 19272650
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. [Microbiological isolates in patients with febrile neutropenia and hematological neoplasias].
    Figuera Esparza M, Carballo M, Silva M, Figueredo A, Avilán J.
    Rev Esp Quimioter; 2006 Sep; 19(3):247-51. PubMed ID: 17099792
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. [Evaluation of antibiotic prophylaxis in neutropenic patients with hematologic malignancies].
    Delarive P, Baumgartner JD, Glauser MP, Cometta A.
    Schweiz Med Wochenschr; 2000 Dec 02; 130(48):1837-44. PubMed ID: 11132527
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. [Bacteremia in hematological malignant disorders].
    Hammerstrøm J, Røym AL, Gran FW.
    Tidsskr Nor Laegeforen; 2008 Aug 14; 128(15):1655-9. PubMed ID: 18704131
    [Abstract] [Full Text] [Related]

  • 36. The spectrum of Gram-positive bloodstream infections in patients with hematologic malignancies, and the in vitro activity of various quinolones against Gram-positive bacteria isolated from cancer patients.
    Rolston KV, Yadegarynia D, Kontoyiannis DP, Raad II, Ho DH.
    Int J Infect Dis; 2006 May 14; 10(3):223-30. PubMed ID: 16439177
    [Abstract] [Full Text] [Related]

  • 37. Fluoroquinolone resistance of Escherichia coli at a cancer center: epidemiologic evolution and effects of discontinuing prophylactic fluoroquinolone use in neutropenic patients with leukemia.
    Kern WV, Klose K, Jellen-Ritter AS, Oethinger M, Bohnert J, Kern P, Reuter S, von Baum H, Marre R.
    Eur J Clin Microbiol Infect Dis; 2005 Feb 14; 24(2):111-8. PubMed ID: 15714332
    [Abstract] [Full Text] [Related]

  • 38. Reappraisal with meta-analysis of the addition of Gram-positive prophylaxis to fluoroquinolone in neutropenic patients.
    Cruciani M, Malena M, Bosco O, Nardi S, Serpelloni G, Mengoli C.
    J Clin Oncol; 2003 Nov 15; 21(22):4127-37. PubMed ID: 14615441
    [Abstract] [Full Text] [Related]

  • 39. Effect of discontinuing prophylaxis with norfloxacin in patients with hematologic malignancies and severe neutropenia. A matched case-control study of the effect on infectious morbidity.
    Martino R, Subira M, Altés A, López R, Sureda A, Domingo-Albós A, Pericas R, Brunet S.
    Acta Haematol; 1998 Nov 15; 99(4):206-11. PubMed ID: 9644298
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.